Changing trends in the decision-making preferences of women with early breast cancer
โ Scribed by L. J. M. Caldon; S. J. Walters; M. W. R. Reed
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 113 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0007-1323
- DOI
- 10.1002/bjs.5964
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Background
Previous studies have indicated a predominance of passive decision-making styles among women with early-stage breast cancer in the UK offered a choice between breast-conserving surgery (BCS) and mastectomy. The aim of this study was to determine current decision-making styles and establish their association with operation choice and breast unit mastectomy rate.
Methods
A questionnaire survey was conducted among women from three specialist breast units representing high, medium and low case mix-adjusted mastectomy rates.
Results
Of 697 consecutive patients, 356 (51ยท1 per cent) completed the questionnaire, a mean of 6ยท9 (range 1ยท3โ48ยท6) weeks after surgery. Some 262 women (73ยท6 per cent) underwent BCS and 94 (26ยท4 per cent) had a mastectomy. Some 218 patients (61ยท2 per cent) achieved their preferred decision-making style. The proportions of women achieving an active decision-making style were high, particularly for those choosing mastectomy (83 versus 58ยท0 per cent for BCS; P < 0ยท001) and in the high mastectomy rate unit (79ยท6 versus 53 and 52ยท2 per cent for medium and low rate units respectively; P < 0ยท001).
Conclusion
More women chose an active decision-making style than in previous UK studies. The provision of greater treatment selection autonomy to women suitable for BCS may not reduce mastectomy rates.
๐ SIMILAR VOLUMES
This study addressed issues regarding the decision-making process used by women who had mastectomy as their surgical treatment for breast cancer. The seven criteria for quality decision-making and the conflict model proposed by Janis and Mann (1977) were used as the study's conceptual framework alon
Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge
and public health agencies have worked to promote the early detection and the early treatment of cancer, With respect to the breast, for instance, both patients and physicians have been urged to seek out the small asymptomatic nodules and to have those that are at all suspicious removed. If this pr
## BACKGROUND: In 2002, the US Food and Drug Administration approved an implantable balloon catheter that delivers accelerated partial breast irradiation (APBI) after breast-conserving surgery (BCS). The objective of the current study was to determine the use of implantable APBI (IAPBI) in the Uni